{
    "clinical_study": {
        "@rank": "129465", 
        "arm_group": {
            "arm_group_label": "Abiraterone Acetate and Prednisone", 
            "arm_group_type": "Experimental", 
            "description": "abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles"
        }, 
        "brief_summary": {
            "textblock": "The primary goal is to prospectively estimate the median radiographic PFS of African\n      American and Caucasian men with mCRPC to abiraterone acetate and prednisone."
        }, 
        "brief_title": "Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a non-comparative pilot open-label, parallel arm, multicenter study of abiraterone\n      acetate in African American and Caucasian men with mCRPC. Patients will self-report on race\n      and 50 patients will be enrolled into each group.  Patients will be treated on open-label\n      treatment until evidence of disease progression as defined by Prostate Cancer Working Group\n      Two (PCWG2) definition or until two years at which point they will roll over to the standard\n      of care at that time.  The study agent abiraterone acetate will be administered by the\n      patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles\n      throughout the treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, age \u2265 18 years\n\n          -  Karnofsky performance status \u2265 70\n\n          -  Life expectancy of \u2265 12 weeks\n\n          -  Willing to take abiraterone acetate on an empty stomach; no food should be consumed\n             at least two hours before and for at least one hour after the dose of abiraterone\n             acetate is taken, and should be able to swallow tablets whole, without\n             crushing/chewing tablets\n\n          -  Patients who have partners of childbearing potential must be willing to use a method\n             of birth control with adequate barrier protection as determined to be acceptable by\n             the principal investigator and sponsor during the study and for 1 week after last\n             dose of abiraterone acetate\n\n          -  Adequate laboratory parameters\n\n          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate.  Histologic\n             variants of prostate cancer, including neuroendocrine features and small cell\n             carcinoma of the prostate are excluded\n\n          -  Radiographic evidence of metastatic disease based on RECIST 1.1 Criteria\n\n          -  Ongoing ADT using an LHRH agonist (e.g. leuprolide, goserelin) or antagonist (e.g.\n             degarelix) must continue on therapy unless prior bilateral orchiectomy has been\n             performed.  Screening serum testosterone must be <50 ng/dl\n\n          -  Evidence of disease progression on ADT (2 consecutive PSA levels 50% or greater above\n             the PSA nadir achieved on ADT and separated at least 1 week apart, OR \u2022 CT or MRI\n             based evidence of disease progression (soft tissue, nodal or visceral disease\n             progression) according to PCWG2 criteria or RECIST 1.1 criteria, or at least 1 new\n             bone scan lesion as compared to the most immediate prior radiologic studies)\n\n          -  A minimum of 4 weeks elapsed off of antiandrogen therapy prior to registration (i.e.\n             flutamide, nilutamide) and 6 weeks for bicalutamide, without evidence of an\n             anti-androgen withdrawal response\n\n          -  A minimum of 4 weeks from any major surgery prior to registration\n\n          -  Ability to swallow, retain, and absorb oral medication\n\n        Exclusion Criteria:\n\n          -  Prior treatment with abiraterone acetate\n\n          -  Active infection or other medical condition that would make prednisone/prednisolone\n             (corticosteroid) use contraindicated\n\n          -  Any chronic medical condition requiring a higher dose of corticosteroid than 5mg\n             prednisone/prednisolone bid\n\n          -  Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or\n             prednisone or their excipients\n\n          -  Pathological finding consistent with small cell carcinoma of the prostate\n\n          -  Liver or visceral organ metastasis\n\n          -  Have a history of gastrointestinal disorders (medical disorders or extensive surgery)\n             that may interfere with the absorption of the study agents\n\n          -  Known brain metastasis\n\n          -  Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC\n\n          -  Previously treated with ketoconazole for prostate cancer for greater than 7 days\n\n          -  Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4\n             weeks of Cycle 1, Day 1\n\n          -  Uncontrolled hypertension (systolic BP \u2265 160 mmHg or diastolic BP \u2265 95 mmHg)\n\n          -  Poorly controlled diabetes\n\n          -  Active or symptomatic viral hepatitis or chronic liver disease\n\n          -  History of pituitary or adrenal dysfunction\n\n          -  Clinically significant heart disease as evidenced by myocardial infarction, or\n             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction\n             measurement of < 50% at baseline\n\n          -  Atrial Fibrillation or other cardiac arrhythmia requiring therapy\n\n          -  Other malignancy, except non-melanoma skin cancer, with a \u2265 30% probability of\n             recurrence within 24 months\n\n          -  Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1\n\n          -  Any condition which, in the opinion of the investigator, would preclude participation\n             in this trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940276", 
            "org_study_id": "Pro00046383", 
            "secondary_id": "212082PCR2018"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abiraterone Acetate and Prednisone", 
                "intervention_name": "Abiraterone acetate", 
                "intervention_type": "Drug", 
                "other_name": "Zytiga"
            }, 
            {
                "arm_group_label": "Abiraterone Acetate and Prednisone", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prostate cancer", 
            "metastatic", 
            "castrate resistant", 
            "abiraterone acetate", 
            "prednisone", 
            "metastatic prostate cancer"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "carolyn.winters@duke.edu", 
                    "last_name": "Carol Winters, RN", 
                    "phone": "919-668-8577"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Daniel George, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kim.ward@duke.edu", 
                    "last_name": "Kim Ward, RN", 
                    "phone": "919-419-5410"
                }, 
                "facility": {
                    "address": {
                        "city": "Henderson", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27536"
                    }, 
                    "name": "Maria Parham Medical Center"
                }, 
                "investigator": {
                    "last_name": "Linda Sutton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kim.ward@duke.edu", 
                    "last_name": "Kim Ward, RN", 
                    "phone": "919-419-5410"
                }, 
                "facility": {
                    "address": {
                        "city": "Laurinburg", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28352"
                    }, 
                    "name": "Scotland Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Linda Sutton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer", 
        "overall_contact": {
            "email": "carolyn.winters@duke.edu", 
            "last_name": "Carol Winters, RN", 
            "phone": "919-668-8577"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Daniel George, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Radiographic PFS based on PCWG2 criteria or based on the onset of a skeletal related event. Imaging obtained every 12 weeks.", 
            "measure": "Median radiographic progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "every 12 weeks, up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940276"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "RECIST 1.1 defined radiologic response rates and incidence of bone flares", 
                "measure": "Change in radiologic response rates", 
                "safety_issue": "No", 
                "time_frame": "every 12 weeks, up to 2 years"
            }, 
            {
                "description": "Duration of PSA response", 
                "measure": "Change in PSA response", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks, up to 2 years"
            }, 
            {
                "description": "Time to PSA nadir", 
                "measure": "Time to PSA nadir", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks, up to 2 years"
            }, 
            {
                "description": "Percent of men who achieve a PSA < 0.1", 
                "measure": "Percent of men who achieve a PSA < 0.1", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks, up to 2 years"
            }, 
            {
                "description": "Safety (NCI CTC v4.0) and tolerability, particularly incidence and grade of hypertension in the two populations", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}